Group 1 - Cinda Biologics has reached a global strategic cooperation with Takeda Pharmaceutical, aiming to accelerate the development of new generation IO and ADC therapies, with a total deal value potentially reaching $11.4 billion [1] - The collaboration includes two late-stage therapies, IBI363 and IBI343, and an early-stage project, IBI3001, with an upfront payment of $1.2 billion, including $100 million in strategic equity investment [1] - Cinda Biologics is expected to maximize the long-term commercialization prospects of IBI363 and IBI343 globally, leveraging Takeda's strong presence in the gastrointestinal oncology field [1] Group 2 - Shouyao Holdings announced that its self-developed RET inhibitor, SY-5007, has received acceptance for a new drug application for treating RET fusion-positive locally advanced or metastatic non-small cell lung cancer [2] - SY-5007 is a highly selective small molecule RET tyrosine kinase inhibitor and is among the fastest progressing fully domestic RET inhibitors in clinical research [2] - If approved, SY-5007 will fill the gap in domestic RET inhibitors, as currently only two RET inhibitors, pralsetinib and selpercatinib, have been approved globally [2] Group 3 - Dongya Pharmaceutical has been ordered to rectify discrepancies between the use of raised funds and disclosures in its IPO prospectus, as identified by the Zhejiang Securities Regulatory Bureau [3] - The company failed to timely follow the review procedures regarding the actual use of raised funds, leading to inaccurate disclosures [3] - This incident highlights the need for listed companies to enhance transparency and compliance in information disclosure [3] Group 4 - ST Nuotai reported a revenue of approximately 1.527 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 21.95%, with a net profit of about 445 million yuan, up 26.92% [4] - In the third quarter, the company achieved revenue of approximately 479 million yuan, a year-on-year growth of 13.82%, and a net profit of about 134 million yuan, increasing by 9.27% [4] - The growth in ST Nuotai's performance is attributed to the rapid increase in demand for peptide raw materials, with oral peptide products expected to become a new growth point for the company [4]